2022 WMIF | Control or Mitigation of the Effects of Chronic Neuroinflammation скачать в хорошем качестве

2022 WMIF | Control or Mitigation of the Effects of Chronic Neuroinflammation

Control or Mitigation of the Effects of Chronic Neuroinflammation Chronic inflammation in the brain is now recognized as a contributor to many neurodegenerative diseases, ranging from Parkinson’s disease to multiple sclerosis to Alzheimer’s disease. Are solutions to these historically intractable neurological diseases imminent or several years away? Are market-making platforms identifiable for neurological diseases? Are there novel genetic targets that can be explored? What are the prospects for cell therapies? Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor of Neurology & Neuroscience, HMS Colin Hill, CEO & Co-Founder, GNS Healthcare Spyros Papapetropoulos, MD, PhD, CMO, Vigil Neuroscience Richard Ransohoff, MD, CMO, Abata Therapeutics Venture Partner, Third Rock Ventures Beth Stevens, PhD, HHMI Investigator, F.M. Kirby Neurobiology Research Program, Boston Children's Hospital; Associate Professor of Neurology, HMS Rudolph Tanzi, PhD, Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS